SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TheraTech (THRT) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey A STEPHENS who wrote (110)7/22/1998 10:20:00 PM
From: Rick Strange  Respond to of 125
 
Jeff, This is the ninth consecutive profitable quarter for the Company. They have four products on the market and 20 in the pipeline. Its co-venture partners reads like "Who's Who" of big Pharma: SmithKline, Pfizer, Eli Lilly, Procter & Gamble, Wyeth-Ayerst and Astra to name a few. Their cash position as of 6/30 was $23,365,922. When is the "Street" going to wakeup to this undervalued jewel?



To: Jeffrey A STEPHENS who wrote (110)7/22/1998 11:14:00 PM
From: Arthur Radley  Read Replies (1) | Respond to of 125
 
Good earnings report and with the test results for female patch due to be released next month, and from presentations in New Orleans it appears that they should be excellent end results, we should start to see some appreciation in this stock.(IMO)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News